|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Number of BM does not impact outcomes in the EGFR/ALK+ NSCLC patients, implying that targeted therapy along with surgery and/or radiation may improve OS irrespective of the number of BM.
|
31648302 |
2020 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with ALK-rearranged or EGFR-mutant NSCLC, ROS1-rearranged NSCLC was less likely to present with extrathoracic metastases (ROS1, 49%; ALK, 75%; EGFR, 72%; P < .01), including brain metastases (ROS1, 9%; ALK, 25%; EGFR, 40%; P < .04).
|
31708389 |
2020 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An EGFR mutation, and ALK and RET gene fusions are risk factors for brain metastasis in advanced NSCLC patients.
|
31769228 |
2020 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A rare case of pulmonary IMS with ALK-1 gene rearrangement and multiple brain metastases responded to three generations of ALK inhibitors.
|
29925295 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations of major drivers, including EGFR, KRAS, TP53, and ALK, were highly concordant between primary NSCLC and matched BMs (>80%), whereas discordance suggested the unique genomic evolution and oncogenic mechanisms of NSCLC BMs.
|
31287555 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic lymphoma kinase ( ALK) gene rearrangements are found in approximately 5% of lung adenocarcinomas and are associated with specific clinical features including a high risk of brain metastases.
|
30786826 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Introduction</b>: Brigatinib is a second-line inhibitor for the treatment of rearranged anaplastic lymphoma kinase (ALK) in lung cancer patients which has significant activity against brain metastases.
|
31328968 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, similar to later-generation anaplastic lymphoma kinase (ALK) inhibitors, osimertinib has improved efficacy against brain metastases.
|
30875928 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among all patients, gender (HR = 1.7, 95%CI = 1.2-2.4, P = 0.006), smoking history (HR = 1.8, 95%CI = 1.3-2.7, P = 0.001), histology (HR = 5.0, 95%CI = 2.4-10.1, P < 0.001), and brain metastases (HR = 1.5, 95%CI = 1.1-2.2, P = 0.017) were independent predictors of EGFR mutation, while age (HR = 2.6, 95%CI = 1.7-4.1, P < 0.001) was an independent predictor of ALK rearrangement.
|
31144459 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several targeted therapies-such as tyrosine kinase inhibitors targeting epidermal growth factor receptors and anaplastic lymphoma kinase-are active in NSCLC and have data to suggested possible effectiveness against brain metastases in these patients.
|
30176786 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.
|
30952820 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, some ALK inhibitors cannot cross the blood-brain barrier (BBB) and thus have little or no efficacy against brain metastases.
|
31425908 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies suggest that stereotactic radiosurgery is preferable to whole-brain radiation therapy and that immune checkpoint inhibitors and therapies targeted to the T790M mutation and ALK can improve outcomes in patients with non-small cell lung cancer and brain metastases.
|
31117044 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we performed a meta-analysis with the aim of assessing the efficacy of ALK inhibitors on BMs.
|
31179082 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article we reviewed the latest literature data concerning the brain metastases and intracranial efficacy of ALK inhibitors in patients with ALK-positive NSCLC.
|
28730760 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brain metastases were more common in ALK-positive cases that were p-PDGFRA-positive compared with those who were p-PDGFRA-negative.
|
30867736 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whereas BM incidence showed a tendency to increase as the M staging increased in patients with EGFR-mutant lung ADC (p < 0.001, trend test), there was no linear trend between M staging and ALK (p = 0.469, trend test) or K-RAS mutations (p = 0.066, trend test).
|
30797488 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there are relatively few studies specified on the treatment of brain metastasis from ALK gene rearrangement NSCLC.
|
31527380 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brain metastases (BM) are associated with high clinical burden in patients with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).
|
29656744 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Areas covered: this paper reviews the available data on alectinib as front-line therapy in patients with ALK-positive NSCLC patients including its activity against brain metastases.
|
29536761 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results Most patients with ALK-positive NSCLC had baseline brain metastases (50 of 79 [63%], phI/II; 80 of 112 [71%] and 73 of 110 [66%] in ALTA arms A and B, respectively), many of whom had no prior brain radiotherapy (23 of 50 [46%], phI/II; 32 of 80 [40%], ALTA arm A; 30 of 73 [41%], arm B).
|
29768119 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present a case of a patient with stage IV anaplastic lymphoma kinase (ALK) positive adenocarcinoma of the lung who underwent stereotactic radiosurgery to her brain metastases and received targeted treatment.
|
29541558 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with NSCLC driven by mutations of <i>ALK</i>, the gene coding for anaplastic lymphoma kinase (ALK), treatment with the ALK inhibitor crizotinib has been found to provide median progression-free survival (PFS) of 10.9 months; however, therapeutic failures and tumor progression to brain metastases are common with crizotinib use, prompting research to find more potent and tolerable ALK inhibitors that target major oncogenic drivers of NSCLC.
|
29467147 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogene-addicted (EGFR- and ALK-positive) non-small cell lung cancers (NSCLCs) are characterized by a unique metastatic neurotropism resulting in a particularly high incidence of brain metastases.
|
30366200 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, patients inevitably develop resistance to ALK inhibitors leading to tumor relapse that commonly manifests in the form of brain metastasis.
|
29455675 |
2018 |